The company said its two preferred uses of cash are share buybacks to return cash to shareholders and targeted M&A, according to TheFlyonTheWall. Boston Scientific said it will always be opportunistic with M&A and will always look to return cash to shareholders.
Furthermore, the company said it is focused on operating income and EPS growth and it feels "comfortable" with tax rate guidance.
Must Read: Warren Buffett's 25 Favorite Stocks
The stock was down 2.32% to $12.62 at 10:40 a.m.